1.FDA approves nivolumab plus ipilimumab combination for intermediate or poor-risk advanced renal cell carcinoma. FDA. Updated April 16, 2018. Accessed March 18, 2021. https://bit.ly/2P30clt2.FDA approves pembrolizumab plus axitinib for advanced renal cell carcinoma. FDA. Updated April 22, 2019. Accessed March 18, 2021. https://bit.ly/3lwyWHZ3.FDA approves avelumab plus axitinib for renal cell carcinoma. FDA. Updated May 15, 2019. Accessed March 18, 2021. https://bit.ly/3eTI3RQ4.Dizman N, Philip EJ, Pal SK. Genomic profiling in renal cell carcinoma. Nat Rev Nephrol. 2020;16(8):435-451. doi:10.1038/s41581-020-0301-x